羟氯喹市场（按适应症、通路和地区划分）

羟氯喹市场规模预计在 2025 年为 6.703 亿美元，预计到 2032 年将达到 9.881 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 5.7%。

羟氯奎在体外对流感、疟疾、冠状病毒和许多其他感染疾病等病毒表现出潜在活性。目前正在研究它作为 COVID-19 治疗的有效性。武汉进行的一项研究表明，使用羟氯喹和Chloroquine治疗后，冠状病毒患者的体温恢復时间和咳嗽缓解时间显着缩短。儘管缺乏有力证据，但由于冠状病毒（COVID-10）流行，对羟氯喹的需求激增。但是，必须监测剂量，因为过量服用羟氯喹会引起危险的副作用，例如嗜睡、视力心室心搏过速、心血管衰竭、抽搐、低血钾、心律不整、心室心搏过速和心室颤动。这会导致呼吸骤停和心臟麻痹，从而危及生命。

市场动态

预计在预测期内，主要企业越来越多地采用非直接成长策略，例如建立合作伙伴关係和协作，以评估羟氯喹锭剂治疗冠状病毒病 (COVID-19) 患者的疗效，将推动市场成长。例如，2020 年 3 月 27 日，製药公司 Rising Pharma Holdings Inc. 与明尼苏达大学感染疾病学院传染病与全球健康系签署了合作协定，探索羟氯喹作为冠状病毒感染疾病(COVID-19) 预防性治疗的可行性。

本研究的主要特点

• 本报告对全球羟氯喹市场进行了详细分析，并提供了预测期 2025-2032 的市场规模和年复合成长率(CAGR)，假设 2024 年为基准年。
• 它还揭示了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新药发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司概况、业绩、产品系列、市场占有率、分销策略、关键发展、策略和未来计划等参数，介绍了全球羟氯喹市场的主要企业概况。
• 本报告的见解将使负责人和公司经营团队能够就未来的药品发布、疾病适应症升级、市场扩张和行销策略做出明智的决策。
• 全球羟氯喹市场报告迎合了该行业的各个相关人员，例如投资者、供应商、製药商、经销商、新进入者和金融分析师。
• 相关人员将透过全球羟氯喹市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 市场机会
• 监管情景
• 产业趋势
• 新疾病适应症的核准与上市
• 推广及行销活动
• 影响分析
• 最新产品发布
• 流行病学
• 合併、收购与合作
• 监管情景
• PEST分析

4. 全球羟氯喹市场-COVID-19影响分析

• 经济影响
• COVID-19流行病学
• 对需求和供给的影响

5. 2020 年至 2032 年全球羟氯喹市场（依适应症划分）

• 介绍
• 疟疾
• 冠状病毒病
• 红斑狼疮
• 类风湿性关节炎

6. 2020-2032 年全球羟氯喹市场（依通路）

• 介绍
• 医院药房
• 零售药局
• 网路药局

7. 2020-2032 年全球羟氯喹市场（按地区）

• 介绍
• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 东南亚国协
  • 澳洲
  • 韩国
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 北非
  • 中部非洲
  • 南非

第八章 竞争态势

• Sanofi
• Amneal Pharmaceuticals, LLC
• Laurus Labs
• Zydus Group
• Prasco, LLC
• Reddy's Laboratories, Ltd
• Cadila Pharmaceuticals
• Novartis AG
• Concordia Pharmaceuticals Inc.（隶属于 Advanz Pharma）
• Covis Pharma GmbH
• Cardinal Health
• Aphena Pharma Solutions
• Mylan NV（Viatris 的子公司）
• McKesson Corporation
• Teva Pharmaceutical Industries Ltd
• Lupin
• Sun Pharmaceutial Industries Ltd

第九章 章节

• 调查方法
• 关于出版商

Hydroxychloroquine Market is estimated to be valued at USD 670.3 Mn in 2025 and is expected to reach USD 988.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Hydroxychlorquine exhibits the potential invitro activity against viruses including influenza, malaria, coronavirus, and many other diseases. The drug is under investigation to determine its efficacy for the treatment of novel coronavirus disease (COVID 19). According to the studies conducted in Wuhan, the body temperature recovery time and the cough remission time of coronavirus patients were significantly reduced with hydroxycloroquine and chloroquine treatment.Despite the absence of strong evidence, the demand for hydroxychloroquine has spiked due to the coronavirus (COVID 19) outbreak. However, the doses of hydroxychloroquine need to be monitored, as its overdose can have dangerous side effects such as drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm, ventricular tachycardia, and ventricular fibrillation. This may lead to sudden respiratory and cardiac arrest, which can be fatal.

Market Dynamics

The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to evaluate the efficacy of hydroxchloroquine tablets for the treatment of patients with coronavirus disease (COVID 19) are expected to propel the market growth over the forecast period. For instance, on March 27, 2020, Rising Pharma Holdings Inc., a pharmaceutical company, entered into a collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease, to explore hydroxchloroquine as preventive treatment for coronavirus disease (COVID 19).

Key features of the study:

• This report provides in-depth analysis of the global hydroxchloroquine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global hydroxchloroquine market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans.
• Key companies covered as a part of this study include Sanofi, Amneal Pharmaceuticals, LLC, Laurus Labs, Zydus Group, Prasco, LLC, Dr. Reddy's Laboratories, Ltd, Cadila Pharmaceuticals, Novartis AG, Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma), Covis Pharma GmbH, Cardinal Health, Aphena Pharma Solutions, Mylan N.V (A subsidiary of Vitris), McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin, Sun Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, disease indication up-gradation, market expansion, and marketing tactics.
• The global hydroxchloroquine market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hydroxchloroquine market.

Detailed Segmentation:

• Global Hydroxychloroquine Market, By Disease Indication:
  • Malaria
  • Coronavirus
  • Lupus Erythematosus
  • Rhematoid Arthritis
• Global Hydroxychloroquine Market, Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Hydroxychloroquine Market, By Region:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Sanofi
  • Amneal Pharmaceuticals, LLC,
  • Laurus Labs,
  • Zydus Group
  • Prasco, LLC
  • Reddy's Laboratories, Ltd
  • Cadila Pharmaceuticals
  • Novartis AG,
  • Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma)
  • Covis Pharma GmbH
  • Cardinal Health
  • Aphena Pharma Solutions,
  • Mylan N.V (A susidary of Vitris)
  • McKesson Corporation
  • Teva Pharmaceutical Industries Ltd
  • Lupin, Sun Pharmaceutical Industries Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Country
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Regulatory Scenario
• Industry Trends
• New Disease Indication Approval/Launches
• Promotion And Marketing Initiatives
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Hydroxychloroquine Market- COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Hydroxychloroquine Market, By Disease Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Malaria
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Coronavirus Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Lupus Erythematosus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Rheumatid Arthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

6. Global Hydroxychloroquine Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

7. Global Hydroxychloroquine Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, Distribution Channel, 2020 - 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amneal Pharmaceuticals, LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Laurus Labs
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Zydus Group
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prasco, LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Reddy's Laboratories, Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cadila Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Covis Pharma GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cardinal Health
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aphena Pharma Solutions
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mylan N.V (A subsidiary of Viatris)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• McKesson Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sun Pharmaceutial Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us